- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01942993
The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
The Effect of BRAF Inhibition With Vemurafenib On The Innate and Adaptive Immune Systems in Patients With Unresectable Stage III or Stage IV Melanoma Expressing a V600 BRAF Mutation
Visão geral do estudo
Descrição detalhada
Approximately 40-60 % of cutaneous melanomas select for a mutation in the BRAF protein which is part of a signaling pathway called the Mitogen Activated Protein Kinase (MAPK) pathway. Over 90% of mutations in BRAF occur at position V600 with the most common being a V600E mutation. Mutation at position V600 of BRAF activates the MAPK pathway which facilitates melanoma proliferation and growth. The response rate to treatment with vemurafenib in patients with stage IV melanoma expressing a V600E BRAF mutation is approximately 50%. A phase III study comparing first line treatment with vemurafenib compared to standard dacarbazine chemotherapy demonstrated a statistically significant overall survival benefit in this patient population. Based on this survival benefit vemurafenib was FDA approved for treatment of stage IV melanoma expressing a V600E BRAF mutation. Vemurafenib is administered at a dose of 960 milligrams orally twice daily.
While targeting BRAF can lead to survival benefits in patients with melanoma expressing BRAF mutation it is becoming increasingly apparent that the immune system is important in modulating the growth of melanoma. As such there are immune therapies FDA approved for the treatment of stage IV melanoma including ipilimumab which confers an overall survival benefit by activating the immune system through inhibition of the CTLA-4 protein expressed on certain T-cells. Little is known about how the exposure of different classes of immune cells to vemurafenib modulates the activity of the immune system. We do know that many melanomas express differentiation antigens which could potentially be recognized by the immune system. This recognition could potentially be utilized in the development of novel immunotherapeutic treatment approaches. The pharmacologic inhibition of the MAPK pathway does lead to increased expression of various melanoma differentiation antigens along with improved recognition by antigen-specific T-lymphocytes. Evaluation of a limited number of tumor biopsy specimens suggest that the infiltration of melanomas by CD4+ and CD8+ T-lymphocytes markedly increases following treatment with a BRAF inhibitor. Furthermore the viability and function (determined using assays for cytokine release assays and cytotoxic activity) of T-lymphocytes was not negatively affected by exposure to vemurafenib at concentrations known to cause anti-tumor effects.
The MAPK pathway is a pathway utilized by many cell types including immune cells and cells in the tumor microenvironment. As such vemurafenib could potentially modulate the activity of the MAPK pathway in the melanoma cells, immune cells, and components of the tumor microenvironment. Effects of vemurafenib on tumor cells may directly lead to changes in antigen presentation and effects on the innate and adaptive immune systems could potentially alter recognition of tumor cells and modulate positively or negatively immune recognition and antitumor activity. Therefore, a better understanding of immune modulation induced by anti-BRAF therapy should provide data to model and develop in a more rational fashion therapies which combine BRAF targeted and immune modulatory agents potentially using such agents as ipilimumab or anti-PD1 or anti-PDL1 antibodies.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
New York
-
New York, New York, Estados Unidos, 11103
- Icahn School of Medicine at Mount Sinai
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histologically confirmed stage IV or unresectable stage III melanoma with documented BRAF V600 mutation
- Age > 18 years
- ECOG Performance Status 0,1, or 2
- Measurable disease by RECIST v1.1
- Adequate organ function: Hemoglobin > 9 g/dl, ANC> 1.5 x 109/L, platelets > 100 x 109/L, AST and ALT < 2.5 x upper limit of normal, bilirubin < 1.5 x upper limit normal, Cr < 1.5 x upper limit normal
- Adequate recovery from prior systemic or local melanoma therapy. No systemic anticancer therapy in the 4 weeks and no ipilimumab in the 6 weeks from planned vemurafenib administration. No radiation therapy in 2 weeks prior to date plan to initiate vemurafenib treatment and no surgery in 3 weeks prior to date of planned vemurafenib administration.
- Agreement for females of childbearing potential use 2 acceptable methods contraception. Men with female partners of childbearing potential must agree to use of latex condom and advise female partner to use additional method contraception during the study and 6 months after discontinuation of vemurafenib
- Negative serum or urine pregnancy test within 7 days prior to and including the morning of day -7 (first potential day of research blood draw and tumor biopsy)
- Agreement not to donate blood or blood products or to donate sperm during the study and for at least 6 months after discontinuation of vemurafenib.
Exclusion Criteria:
- Prior vemurafenib treatment
- Use of oral or intravenous corticosteroids or other immunosuppressive medications such as cyclosporine or azathioprine. Subjects must not have received any systemic immunosuppressive drug such as corticosteroids for at least 2 weeks prior to study entry. Maintenance inhaled corticosteroids for controlled asthma or COPD or maintenance systemic steroids to correct autoimmune endocrinopathy due to prior ipilimumab treatment is allowed as is the use of topical steroids and anti-inflammatory eye drops.
- Symptomatic CNS metastases requiring steroid use.
- No active second malignancy
- Pregnant or breast feeding
- Mean QTc interval > 450 (triplicate ECGs) or history congenital prolonged QT interval
- Any of the following within 3 months prior to study drug administration: myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism
- Inability to swallow pills
- Ongoing cardiac dysrhythmia >2 (per NCI CTCAE, v4.0)
- Unwillingness to practice birth control
- Inability to comply with requirements of the protocol
- Uncontrolled medical illness such as infection requiring intravenous antibiotics.
- Known allergy to treatment medication (vemurafenib)
- Known active or chronic infection with HIV.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Vemurafenib
960 mg (four tablets of 240 mg each) of vemurafenib PO BID
|
Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal.
Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration.
Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed.
Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation.
Dose reductions below 480 mg twice daily are not recommended.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Changes in the Immune Cellular Signature in the Blood Circulation
Prazo: baseline, day 8, and day 57
|
Immuno-fluorescence and flow cytometry will be performed on blood specimens obtained to determine changes in the immune cell signature in the blood on day 8 and day 57 after initiation of vemurafenib treatment as compared to baseline
|
baseline, day 8, and day 57
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Changes in the Immune Cellular Signature in the Tumor
Prazo: baseline, day 8-10, and day 57
|
Immuno-fluorescence and flow cytometry will be performed on tumor specimens obtained to determine changes in the immune cell signature in the tumor on day 8-10 and day 57 after initiation of vemurafenib treatment as compared to baseline
|
baseline, day 8-10, and day 57
|
Changes in Transcriptional Profile in the Blood
Prazo: baseline, day 8, and day 57
|
Global changes in the blood transcriptome in response to vemurafenib therapy will be performed using gene expression arrays.
Change in the blood transcriptosome on day 8 and day 57 as compared to baseline.
|
baseline, day 8, and day 57
|
Change in Transcriptional Profile in Tumor
Prazo: baseline and day 8-10
|
Global changes in the transcriptosome of tumor associated immune cells in response to therapy will be performed using gene expression arrays.
The transcriptosome in tumor will be compared on purified tumor immune cells obtained from a pretreatment tumor biopsy performed at baseline and a second biopsy obtained after starting treatment and obtained between days 8-10.
|
baseline and day 8-10
|
Changes in Dendritic Cell Function in Blood
Prazo: baseline day 8, and day 57
|
change in dendritic cell function at day 8 and day 57 as compared to baseline
|
baseline day 8, and day 57
|
Changes in Dendritic Cell Function in Tumor
Prazo: baseline and day 8-10
|
Changes in dendritic cell function in tumor on day 8-10 as compared to baseline
|
baseline and day 8-10
|
Changes in Macrophage Function in Blood
Prazo: baseline, day 8, and day 57
|
Changes in macrophage function in blood at day 8 and day 57 as compared to baseline
|
baseline, day 8, and day 57
|
Changes in Macrophage Function in Tumor
Prazo: baseline and day 8-10
|
changes in macrophage function in tumor on day 8-10 as compared to baseline
|
baseline and day 8-10
|
Changes in Global T Cell Function in Blood
Prazo: baseline, day 8, and day 57
|
changes in global T cell function in blood on day 8 and day 57 as compared to baseline
|
baseline, day 8, and day 57
|
Changes in Global T Cell Function in Tumor
Prazo: baseline and day 8-10
|
Changes in Global T cell function in Tumor on day 8 as compared to baseline
|
baseline and day 8-10
|
Changes in Tumor Antigen Specific T Cell Function in Blood
Prazo: baseline, day 8, day 15 and day 126
|
Changes in Tumor Antigen Specific T cell Function using CD154 induction assay on day 8, day 15 and day 126 as compared to baseline
|
baseline, day 8, day 15 and day 126
|
Changes in Histocytometry of Tumor
Prazo: baseline and day 8-10
|
Changes in Histocytometry of tumor on day 8-10 as compared to baseline.
Histocytometry is a novel microscopic analytical method (Gerner et al. 2012) which combines the advantages of flow cytometry and Microscopic techniques.
This techniques allows for the visualization and quantification of phenotypically complex cellular subsets and provides spatial and cell-cell interactions.
|
baseline and day 8-10
|
Response to Vemurafenib Treatment
Prazo: up to 57 days
|
Response to vemurafenib treatment based on changes in tumor burden using CT or MRI imaging studies.
Response are categorized as complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD),
|
up to 57 days
|
Number of Participants Who Developed of Cutaneous Squamous Cell Carcinomas
Prazo: up to 5 months
|
Number of participants who developed cutaneous squamous cell carcinomas while on the study
|
up to 5 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias por Tipo Histológico
- Neoplasias
- Tumores Neuroectodérmicos
- Neoplasias, Células Germinativas e Embrionárias
- Neoplasias, Tecido Nervoso
- Tumores Neuroendócrinos
- Nevos e Melanomas
- Melanoma
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores Enzimáticos
- Agentes Antineoplásicos
- Inibidores de proteína quinase
- Vemurafenibe
Outros números de identificação do estudo
- GCO 13-0427
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Vemurafenib
-
Memorial Sloan Kettering Cancer CenterGenentech, Inc.Rescindido
-
Hoffmann-La RocheConcluídoMelanoma malignoEstados Unidos, Austrália
-
Hoffmann-La RocheConcluídoMelanoma Maligno, NeoplasiasEspanha, Nova Zelândia, Hungria, Sérvia, Alemanha, Portugal, Holanda, Grécia, Austrália
-
Hoffmann-La RocheRescindidoMelanoma malignoEstados Unidos, França, Austrália, Reino Unido, Itália, Espanha, Alemanha, Israel, Polônia, Eslováquia
-
University of California, San FranciscoNovartisConcluídoMelanoma Metastático Mutante BRAFEstados Unidos
-
Daiichi Sankyo, Inc.PlexxikonRescindidoMelanoma irressecável BRAF com mutação V600 | Melanoma metastático BRAF com mutação V600 | Melanoma metastático de estágio III ou estágio IV que não foi tratado anteriormente com um inibidor seletivo de BRAFEstados Unidos, Alemanha, França
-
Celldex TherapeuticsMemorial Sloan Kettering Cancer CenterConcluídoCâncer de tireoideEstados Unidos
-
PfizerAtivo, não recrutandoMelanomaCanadá, Estados Unidos, Espanha, Alemanha, Republica da Coréia, Austrália, Tcheca, Holanda, França, Hungria, Reino Unido, Suíça, Cingapura, Federação Russa, Itália, Japão, Israel, Brasil, Portugal, México, Grécia, Argentina, Polônia, Co... e mais
-
Inova Health Care ServicesGenentech, Inc.Retirado
-
CytomX TherapeuticsConcluídoLinfoma | Tumor SólidoEstados Unidos, Holanda, Polônia, Espanha, Ucrânia, Reino Unido